Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is roughly 9.11 % above the present share price of $76.07.
Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the first quarter of 2021.
The analysts priced targets range from a high of $101 to a low of $61.
In the latest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is $99.57 billion.
According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0-5 stars ranking scale, with an average return of 11.5 % as well as a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management strategies. The retail or Long Term Care segment has selling of prescribed drugs as well as assortment of general merchandise.
The Health Care Benefits segment offers quite traditional, consumer-directed and voluntary health insurance products as well as similar services, which includes medical, pharmacy, dental, behavioural health, medical relief abilities. The Corporate segment involves in offering management as well as administrative services. The company was developed by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.